Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia.

Abstract

We report the case of a 49-year-old woman with homozygous familial hypercholesterolemia and a complicated cardiovascular history, treated for 5 years with a microsomal triglyceride transfer protein inhibitor in addition to her other lipid-lowering therapy.

• Authors: Anna Raper, Daniel M Kolansky, Bruce S Sachais, Emma A Meagher, Amanda L Baer, Marina Cuchel
• Journal: Journal of clinical lipidology (J Clin Lipidol) 2015 Jan-Feb Vol. 9 Issue 1 Pg. 107-12 ISSN: 1933-2874 [Print] United States
• PMID: 25670368 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
• Copyright: Copyright © 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Chemical References

• Anticholesteremic Agents
• Anticoagulants
• BMS201038
• Benzimidazoles
• Carrier Proteins
• microsomal triglyceride transfer protein
• Cholesterol
• Aspartate Aminotransferases
• Alanine Transaminase

Topics

• Alanine Transaminase (blood)
• Anticholesteremic Agents (adverse effects, therapeutic use)
• Anticoagulants (therapeutic use)
• Aspartate Aminotransferases (blood)
• Benzimidazoles (adverse effects, therapeutic use)
• Blood Component Removal
• Carrier Proteins (antagonists & inhibitors, metabolism)
• Cholesterol (blood)
• Female
• Hematoma (diagnostic imaging, drug therapy, etiology)
• Humans
• Hyperlipoproteinemia Type II (drug therapy)
• Liver Function Tests
• Magnetic Resonance Imaging
• Middle Aged
• Radiography